429 related articles for article (PubMed ID: 32277501)
1. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
2. [Factor IX assays in treated hemophilia B patients].
Pouplard C; Jeanpierre E; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Ternisien C; Toulon P; Voisin S; Nougier C;
Ann Biol Clin (Paris); 2019 Feb; 77(1):41-52. PubMed ID: 30799297
[TBL] [Abstract][Full Text] [Related]
3. [Factor VIII assays in treated hemophilia A patients].
Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
5. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
6. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
[TBL] [Abstract][Full Text] [Related]
7. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
Peyvandi F; Oldenburg J; Friedman KD
J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
[TBL] [Abstract][Full Text] [Related]
9. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
[No Abstract] [Full Text] [Related]
10. Performance evaluation of Revohem
Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
[TBL] [Abstract][Full Text] [Related]
11. The availability of new drugs for hemophilia treatment.
Morfini M; Marchesini E
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):721-738. PubMed ID: 32515633
[TBL] [Abstract][Full Text] [Related]
12. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
Abraham S; Duncan EM
Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
14. Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Fukutake K; Kobayashi T; Sommer JM; Hirakata T
Int J Lab Hematol; 2020 Apr; 42(2):162-169. PubMed ID: 31820573
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar RA; Strandberg K; Shima M; Adcock DM
Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
[TBL] [Abstract][Full Text] [Related]
18. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Kitchen S; Tiefenbacher S; Gosselin R
Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
[TBL] [Abstract][Full Text] [Related]
19. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
20. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
